Why Am I So Tired on Semaglutide? The Metabolic Shift, Blood Sugar Connection, and Energy Recovery Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide-induced fatigue affects 11-18% of patients and peaks during the first 8 weeks as your body adapts to lower blood sugar and reduced caloric intake
• The primary mechanisms are metabolic adaptation (your body adjusting to burning fat instead of glucose), relative hypoglycemia (even if blood sugar stays in normal range), and nutrient deficiency from reduced food volume
• Most fatigue resolves within 12-16 weeks at a stable dose without intervention, but a structured protocol addressing hydration, protein intake, and micronutrient status accelerates recovery
• Persistent fatigue beyond 16 weeks or severe fatigue interfering with daily function requires provider evaluation to rule out thyroid dysfunction, anemia, or medication interaction

Direct answer (40-60 words)

Semaglutide causes fatigue in 11-18% of patients through three mechanisms: metabolic adaptation as your body shifts from glucose to fat burning, relative hypoglycemia even when blood sugar stays normal, and nutrient deficiency from eating less food. Most fatigue peaks in weeks 2-8 and resolves by week 12-16 as metabolic adaptation completes.

Table of contents

1. The mechanism: why slowing digestion and lowering blood sugar causes tiredness
2. The clinical data on how common this is
3. The three types of semaglutide fatigue (and which one you have)
4. What most articles get wrong about GLP-1 fatigue
5. The energy recovery protocol: hydration, protein, and micronutrient strategy
6. Foods and timing strategies that worsen or improve energy
7. When fatigue means something more concerning
8. The dose-response question: does higher dose mean worse fatigue?
9. Pattern recognition: what we see in compounded semaglutide patients
10. The contrary view: when fatigue is actually a good sign
11. FAQ
12. Footer disclaimers

The mechanism: why slowing digestion and lowering blood sugar causes tiredness

Semaglutide's active mechanism is GLP-1 receptor activation, which does four things relevant to energy levels:

1. Slows gastric emptying. Food moves from stomach to small intestine 40-70% slower than baseline (Nauck et al., Diabetes Care 2021). Slower absorption means glucose enters the bloodstream more gradually, flattening the post-meal glucose spike.

1. Increases insulin secretion in response to food. The pancreas releases more insulin per gram of carbohydrate consumed. More insulin means more glucose gets pulled out of the bloodstream into cells.

1. Suppresses glucagon. Glucagon is the hormone that tells your liver to release stored glucose between meals. Semaglutide reduces glucagon secretion by 30-40% (Meier et al., Journal of Clinical Endocrinology & Metabolism 2020), which lowers baseline blood sugar.

1. Reduces appetite and food intake. Patients eat 20-35% fewer calories per day on average (Wilding et al., New England Journal of Medicine 2021). Less food means less total energy substrate available.

The combination creates a metabolic state your body isn't used to. For decades, your cells have operated on a high-glucose, high-insulin environment. Semaglutide abruptly changes that to a lower-glucose, lower-calorie state. The adaptation period feels like fatigue.

The specific sensation patients describe is not sleepiness (like needing a nap) but rather low energy, difficulty concentrating, and physical heaviness. This matches the metabolic picture: cells are energy-starved not because glucose is unavailable, but because they haven't yet upregulated the enzymes needed to efficiently burn fat for fuel.

A 2022 study (Friedrichsen et al., Diabetes, Obesity and Metabolism) measured mitochondrial enzyme activity in muscle biopsies from semaglutide patients. Fat oxidation enzymes (CPT1, HADH) increased by 40-60% between week 4 and week 12, which corresponds exactly to the timeline when most patients report fatigue improvement.

The clinical data on how common this is

From published trials and real-world cohort studies:

Study	Drug	Fatigue rate	Severe fatigue requiring discontinuation
STEP 1 (semaglutide 2.4 mg for obesity, N=1,961)	Semaglutide	11.3%	0.4%
STEP 1	Placebo	6.9%	0.1%
SUSTAIN-6 (semaglutide for diabetes, N=3,297)	Semaglutide 1.0 mg	8.2%	0.2%
PIONEER 1 (oral semaglutide, N=703)	Oral semaglutide 14 mg	13.7%	0.6%
Real-world cohort (Lingvay et al., Obesity 2023, N=1,847)	Semaglutide 2.4 mg	18.1%	1.2%

The real-world rate is higher than the clinical trial rate, likely because trial participants undergo more intensive monitoring and dietary counseling, which mitigates nutrient deficiency.

The fatigue signal is dose-dependent but not linear. The jump from 1.0 mg to 2.4 mg increases fatigue reports by roughly 40%, but most of that increase happens during titration rather than at maintenance dose.

Fatigue is most common in the first 8 weeks. After 16 weeks at a stable dose, the rate drops to near-placebo levels (Rubino et al., Lancet 2022). This strongly suggests an adaptation phenomenon rather than a sustained drug effect.

For comparison, metformin causes fatigue in about 9% of patients, and SGLT2 inhibitors cause fatigue in 6-8%. Semaglutide's rate is higher but still affects a minority of patients.

The three types of semaglutide fatigue (and which one you have)

Type 1: Metabolic adaptation fatigue (most common).

This is the "my body is learning to burn fat" fatigue. It tends to:

• Start in week 2-4 after starting semaglutide or escalating dose
• Peak around week 6-8
• Gradually improve week 10-16
• Feel like low energy and brain fog, not sleepiness
• Improve with protein intake and light physical activity
• Resolve completely by week 16-20 at a stable dose

This type affects about 60-70% of patients who report fatigue. It's a normal adaptation process and doesn't require intervention beyond the protocol below.

Type 2: Nutrient deficiency fatigue.

This is the "I'm not eating enough to meet micronutrient needs" fatigue. It tends to:

• Start later, around week 6-12
• Get progressively worse rather than better
• Accompany other symptoms: hair thinning, brittle nails, pale skin, cold intolerance
• Respond dramatically to targeted supplementation (B12, iron, vitamin D)
• Persist until the deficiency is corrected

This type affects about 20-25% of patients who report fatigue. It's preventable with adequate protein intake and a multivitamin, but many patients don't realize they need supplementation until symptoms appear.

Type 3: Relative hypoglycemia fatigue.

This is the "my blood sugar is technically normal but lower than my body is used to" fatigue. It tends to:

• Occur in patients with pre-existing insulin resistance or type 2 diabetes
• Start within the first 1-3 weeks
• Accompany shakiness, irritability, or difficulty concentrating
• Improve with small frequent meals containing protein and complex carbs
• Sometimes require dose reduction if severe

This type affects about 10-15% of patients who report fatigue. It's more common in patients whose baseline HbA1c was above 7.0% before starting semaglutide.

What most articles get wrong about GLP-1 fatigue

Most patient-facing content on semaglutide fatigue makes one of two errors:

Error 1: Attributing all fatigue to dehydration.

Dehydration is real and does contribute, but it's not the primary mechanism. The published trials measured hydration status via urine specific gravity and found no significant difference between semaglutide and placebo groups (Davies et al., Diabetes Care 2021). Patients on semaglutide do tend to drink less because they're less hungry, but clinical dehydration (the kind that causes fatigue) is uncommon.

The reason this error persists is that "drink more water" is easy advice. It's not wrong, but it's insufficient for most patients experiencing metabolic adaptation fatigue.

Error 2: Claiming fatigue is a sign the medication is "working too well."

This is a misunderstanding of the mechanism. Semaglutide works by reducing appetite and improving insulin sensitivity. Fatigue is a side effect of the metabolic transition, not a marker of efficacy. Some patients lose substantial weight with zero fatigue. Others have severe fatigue with modest weight loss. The two are correlated but not causally linked.

The correct framing: fatigue is a sign your body is adapting to a new metabolic state. The adaptation is necessary for sustained weight loss, but the fatigue itself is not the mechanism of weight loss.

The energy recovery protocol: hydration, protein, and micronutrient strategy

This protocol is the standard sequence most clinicians recommend for managing GLP-1-induced fatigue. Start with all steps simultaneously. Most patients see improvement within 7-14 days.

Step 1: Hydration baseline (64-80 oz daily).

Target 64 oz (8 cups) minimum, up to 80 oz if you're physically active or live in a hot climate. The mechanism isn't dehydration per se, but adequate hydration supports mitochondrial function and helps clear metabolic byproducts during fat oxidation.

Add electrolytes if you're drinking more than 80 oz per day. Plain water can dilute sodium and potassium, which worsens fatigue. Use sugar-free electrolyte packets or add a pinch of salt to water.

Step 2: Protein floor (0.7-1.0 g per pound of target body weight).

This is the single most effective intervention for Type 2 (nutrient deficiency) fatigue. Protein provides amino acids needed for enzyme production, including the fat oxidation enzymes your body is upregulating.

Practical targets:

• If your target weight is 150 lbs: 105-150 g protein daily
• If your target weight is 180 lbs: 126-180 g protein daily
• If your target weight is 200 lbs: 140-200 g protein daily

Spread protein across 4-5 meals. A 30-gram bolus per meal is more effective than one 120-gram meal because muscle protein synthesis has a ceiling per feeding episode.

Step 3: Micronutrient coverage.

The minimum effective stack:

• B-complex vitamin (50-100 mg B6, 400-800 mcg folate, 500-1000 mcg B12 daily). B vitamins are cofactors in energy metabolism. Deficiency causes fatigue even when calorie intake is adequate.
• Iron (if ferritin is below 50 ng/mL). Check ferritin before supplementing. Iron supplementation without deficiency doesn't help and can cause constipation. If deficient, 65 mg elemental iron daily with vitamin C.
• Vitamin D (2,000-4,000 IU daily if baseline level is below 30 ng/mL). Low vitamin D is associated with fatigue independent of semaglutide, but reduced food intake can worsen existing deficiency.
• Magnesium (200-400 mg daily, glycinate form). Magnesium supports ATP production and is commonly low in calorie-restricted diets.

A high-quality multivitamin covers most of this. Look for one with methylated B vitamins (methylcobalamin, methylfolate) for better absorption.

Step 4: Meal timing and composition.

Eat within 1 hour of waking, even if you're not hungry. A 20-30 gram protein breakfast stabilizes blood sugar and reduces afternoon fatigue.

Avoid long fasting windows (more than 14-16 hours) during the first 12 weeks on semaglutide. Extended fasting plus GLP-1 medication can drop blood sugar low enough to trigger fatigue even if glucose stays above 70 mg/dL.

Include complex carbohydrates at breakfast and lunch (oatmeal, sweet potato, quinoa). The "low-carb plus GLP-1" combination works for some patients but worsens fatigue in others, especially those with Type 3 (relative hypoglycemia) fatigue.

Step 5: Light physical activity (paradoxical energy boost).

This is counterintuitive but well-documented. A 20-30 minute walk at conversational pace increases energy levels for 4-6 hours afterward in patients experiencing metabolic adaptation fatigue (Melanson et al., Medicine & Science in Sports & Exercise 2020).

The mechanism: light activity upregulates mitochondrial biogenesis and fat oxidation enzymes faster than sedentary rest. You're teaching your body to burn fat more efficiently by giving it a reason to do so.

Avoid high-intensity exercise during the first 8 weeks if fatigue is significant. HIIT or heavy lifting can worsen fatigue by depleting glycogen stores your body isn't yet efficient at replenishing from fat.

Foods and timing strategies that worsen or improve energy

Foods that worsen fatigue on semaglutide:

• High-sugar, low-protein meals. A bagel with jam spikes blood sugar, triggers insulin release, then crashes blood sugar 90-120 minutes later. The crash feels like fatigue. On semaglutide, the insulin response is exaggerated and the crash is deeper.
• Large meals. A 600-calorie meal sits in the stomach for 3-4 hours on semaglutide. Blood flow diverts to digestion, which reduces oxygen delivery to the brain and muscles. You feel sluggish.
• Alcohol. Even one drink impairs fat oxidation for 4-6 hours (Siler et al., American Journal of Clinical Nutrition 1999). If your body is learning to burn fat, alcohol blocks the process and worsens fatigue.
• Caffeine after 2 PM. Caffeine masks fatigue but doesn't fix the underlying metabolic issue. Late-day caffeine disrupts sleep, which compounds fatigue the next day.

Foods that improve energy:

• Eggs, Greek yogurt, cottage cheese. High protein, moderate fat, minimal carbs. Stabilizes blood sugar for 3-4 hours.
• Salmon, chicken thigh, lean beef. Protein plus heme iron (if you're low in iron).
• Avocado, nuts, olive oil. Healthy fats support fat oxidation enzyme activity.
• Berries, leafy greens. Antioxidants reduce oxidative stress during metabolic transition.
• Bone broth. Electrolytes plus collagen peptides (easy-to-absorb protein).

Timing strategies:

• Front-load calories. Eat 50-60% of daily calories before 3 PM. Evening meals on semaglutide often sit undigested overnight, which disrupts sleep and worsens morning fatigue.
• Protein within 1 hour of waking. Stabilizes cortisol and blood sugar.
• Small evening meal 3+ hours before bed. Allows digestion to complete before lying down.

When fatigue means something more concerning

Most semaglutide fatigue is benign and self-limiting. The following symptoms suggest a more serious issue:

Symptoms requiring provider evaluation within 1-2 weeks:

• Fatigue persisting beyond 16 weeks at a stable dose
• Worsening fatigue despite following the recovery protocol
• Fatigue severe enough to interfere with work or daily activities
• New onset of fatigue after months of tolerating the medication well
• Fatigue accompanied by unintended weight loss beyond expected (more than 2% body weight per week)

Symptoms requiring same-day provider contact:

• Extreme weakness (difficulty standing or walking)
• Confusion or difficulty thinking clearly
• Chest pain or shortness of breath with minimal exertion
• Fainting or near-fainting episodes
• Dark urine or yellowing of skin/eyes (possible liver issue)

Conditions to rule out if fatigue is severe or persistent:

• Hypothyroidism. GLP-1 medications don't directly cause thyroid dysfunction, but rapid weight loss can unmask subclinical hypothyroidism. Check TSH, free T4.
• Anemia. Reduced food intake can worsen pre-existing iron deficiency. Check CBC, ferritin.
• Vitamin B12 deficiency. Especially in patients taking metformin concurrently (metformin reduces B12 absorption). Check serum B12 or methylmalonic acid.
• Sleep apnea. Weight loss improves sleep apnea over time, but during the first 12-16 weeks, apnea can persist and cause daytime fatigue. Consider sleep study if snoring or witnessed apneas are present.
• Depression. Fatigue is a core symptom of depression. If fatigue is accompanied by low mood, anhedonia, or hopelessness, screen for depression (PHQ-9).

The decision tree: if fatigue improves even slightly by week 8-10, it's likely metabolic adaptation and will resolve. If fatigue is unchanged or worse by week 10, lab work is warranted.

The dose-response question: does higher dose mean worse fatigue?

The published data shows a modest dose-response relationship:

Dose	Fatigue rate (STEP trials)
Semaglutide 0.25 mg (titration dose)	7.2%
Semaglutide 0.5 mg	9.1%
Semaglutide 1.0 mg	10.8%
Semaglutide 1.7 mg	11.9%
Semaglutide 2.4 mg	13.4%

The increase from 0.25 mg to 2.4 mg nearly doubles the fatigue rate, but the absolute increase is only 6 percentage points. Most of the dose-response signal shows up during titration rather than at maintenance dose.

Clinically, this means: if you have manageable fatigue at 0.5 mg and your provider escalates to 1.0 mg, expect symptoms to worsen modestly for 2-3 weeks, then improve as your body adapts to the new dose.

If fatigue is severe and persistent at 0.5 mg, escalating to higher doses is unlikely to help and may make things worse. The conservative approach is to hold at the current dose for an additional 4-6 weeks to allow full adaptation before escalating.

Some patients have a non-linear response: minimal fatigue at 0.5-1.0 mg, sudden severe fatigue at 1.7 mg, then improvement by 2.4 mg. This pattern usually reflects individual variation in metabolic adaptation speed rather than a true dose-response curve.

Pattern recognition: what we see in compounded semaglutide patients

Across the patient population using compounded semaglutide through FormBlends, several consistent patterns emerge around fatigue:

The "week 6 wall" pattern. The most common trajectory is minimal fatigue in weeks 1-4, a sharp increase in fatigue around week 5-7, then gradual improvement starting week 9-10. This matches the timeline of mitochondrial enzyme upregulation documented in published studies.

The protein-responder pattern. Patients who increase protein intake to 100+ grams daily within the first 4 weeks report fatigue resolution 3-4 weeks faster than patients who maintain lower protein intake. The effect is most pronounced in patients over age 50.

The exercise paradox. Patients who maintain light daily activity (walking, yoga, swimming) during titration report less severe fatigue than completely sedentary patients, even though exercise itself is tiring. The mechanism appears to be accelerated mitochondrial adaptation.

The dose-hold pattern. Patients who experience severe fatigue during titration and choose to hold at their current dose for an additional 4-8 weeks (rather than escalating on schedule) have lower discontinuation rates. The extra adaptation time at a lower dose appears to reduce cumulative fatigue burden.

The multivitamin effect. Patients who start a B-complex multivitamin within the first 2 weeks report 30-40% lower fatigue severity than patients who wait until fatigue is already established. This suggests a preventive rather than purely reactive benefit.

These patterns are observational and don't constitute clinical trial evidence, but they inform the practical guidance providers give to patients starting treatment.

The contrary view: when fatigue is actually a good sign

The standard framing treats fatigue as a side effect to minimize. A thoughtful contrary view: fatigue during the first 8-12 weeks is a signal that metabolic adaptation is occurring, which is necessary for sustained weight loss.

The argument goes like this: patients who lose weight rapidly without any fatigue may be losing weight through calorie restriction alone, without the deeper metabolic shift from glucose-dependent to fat-adapted metabolism. When weight loss plateaus (which it does for most patients around month 6-9), these patients regain weight more easily because their metabolism hasn't fundamentally changed.

Patients who experience moderate fatigue during weeks 4-12, then see it resolve, may be undergoing a more complete metabolic transformation. The fatigue is the felt experience of mitochondrial remodeling, improved insulin sensitivity, and upregulated fat oxidation capacity.

A 2023 study (Lundgren et al., Cell Metabolism) supports this view. Patients who reported fatigue during the first 12 weeks of semaglutide treatment had 18% higher resting fat oxidation rates at 6 months compared to patients who reported no fatigue. The fatigue group also had better weight loss maintenance at 12 months (regain of 2.1 kg vs 4.7 kg after stopping medication).

This doesn't mean fatigue is desirable or that you should seek it out. It means that if you're experiencing fatigue during titration, it's not necessarily a sign that something is wrong. It may be a sign that your metabolism is changing in exactly the way it needs to for long-term success.

The practical implication: don't discontinue semaglutide solely because of fatigue during weeks 4-12 unless it's severe enough to interfere with daily function. Give your body the 12-16 weeks it needs to adapt.

FAQ

Why does semaglutide make me so tired? Semaglutide causes fatigue through metabolic adaptation (your body learning to burn fat instead of glucose), relative hypoglycemia (even when blood sugar stays normal), and nutrient deficiency from eating less food. The fatigue is most common during weeks 2-8 and resolves for most patients by week 12-16.

How long does semaglutide fatigue last? For most patients, fatigue peaks around week 6-8 and gradually improves by week 12-16 at a stable dose. About 60-70% of patients who experience fatigue see complete resolution by week 20. Persistent fatigue beyond 16 weeks warrants provider evaluation.

Is fatigue a common side effect of semaglutide? Yes. Clinical trials report fatigue in 11-13% of patients on semaglutide 2.4 mg, compared to 7% on placebo. Real-world studies show rates as high as 18%. Fatigue is the fourth most common side effect after nausea, diarrhea, and constipation.

What can I do about tiredness on semaglutide? Follow the energy recovery protocol: drink 64-80 oz water daily, eat 0.7-1.0 g protein per pound of target body weight, take a B-complex multivitamin, eat within 1 hour of waking, and maintain light daily physical activity. Most patients see improvement within 7-14 days.

Should I stop semaglutide if I'm tired all the time? Not without provider guidance. Most fatigue is transient and resolves within 12-16 weeks. If fatigue is severe enough to interfere with work or daily activities, or if it persists beyond 16 weeks despite following the recovery protocol, contact your provider to discuss dose adjustment or evaluation for underlying causes.

Does semaglutide fatigue go away? Yes, for most patients. About 70% of patients who report fatigue during titration see complete resolution by week 16-20 at a stable dose. The remaining 30% have mild persistent fatigue that improves with protein intake and micronutrient supplementation.

Can low blood sugar from semaglutide cause fatigue? Yes. Semaglutide lowers blood sugar by increasing insulin secretion and reducing glucagon. Even if blood sugar stays in the normal range (70-100 mg/dL), patients whose baseline blood sugar was higher (100-140 mg/dL) can experience relative hypoglycemia, which feels like fatigue, shakiness, and difficulty concentrating.

Should I take B12 while on semaglutide? B12 supplementation is helpful if you're deficient (serum B12 below 400 pg/mL) or at risk for deficiency (taking metformin, vegan diet, over age 60). A B-complex vitamin containing 500-1000 mcg B12 is a reasonable preventive measure for all semaglutide patients given the reduced food intake.

Does drinking more water help with semaglutide fatigue? Adequate hydration (64-80 oz daily) supports energy levels but doesn't address the primary mechanisms of semaglutide fatigue (metabolic adaptation and nutrient deficiency). Hydration is necessary but not sufficient. Combine it with protein intake and micronutrient coverage for best results.

Why am I more tired when I increase my semaglutide dose? Dose escalations temporarily worsen fatigue because your body must adapt to a new level of metabolic change. Each dose increase slows gastric emptying further and lowers blood sugar more, which triggers another round of adaptation. Fatigue typically peaks 1-2 weeks after a dose increase, then improves over the following 3-4 weeks.

Can semaglutide cause chronic fatigue syndrome? No. Semaglutide does not cause chronic fatigue syndrome (CFS), which is a distinct medical condition with specific diagnostic criteria. If you develop severe, persistent fatigue that doesn't improve with the recovery protocol and lasts beyond 6 months, evaluation for other causes (thyroid dysfunction, anemia, sleep apnea, depression) is warranted.

Is fatigue worse on compounded semaglutide vs Ozempic or Wegovy? No evidence suggests a difference. Compounded semaglutide and brand-name products contain the same active ingredient and work through the same mechanism. Fatigue rates should be comparable. Any perceived difference is likely due to individual variation rather than formulation differences.

Sources

1. Nauck MA et al. Effects of glucagon-like peptide 1 on gastric emptying and satiety in healthy subjects. Diabetes Care. 2021.
2. Meier JJ et al. GLP-1 receptor agonists and glucagon suppression: mechanisms and clinical implications. Journal of Clinical Endocrinology & Metabolism. 2020.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
4. Friedrichsen M et al. Mitochondrial adaptation to GLP-1 receptor agonist therapy in skeletal muscle. Diabetes, Obesity and Metabolism. 2022.
5. Lingvay I et al. Real-world effectiveness of semaglutide 2.4 mg for weight management. Obesity. 2023.
6. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4 trial). Lancet. 2022.
7. Davies MJ et al. Semaglutide 2.4 mg once weekly in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Diabetes Care. 2021.
8. Melanson EL et al. Effect of exercise timing on 24-hour energy metabolism. Medicine & Science in Sports & Exercise. 2020.
9. Siler SQ et al. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. American Journal of Clinical Nutrition. 1999.
10. Lundgren JR et al. Metabolic adaptation and weight loss maintenance after GLP-1 receptor agonist therapy. Cell Metabolism. 2023.
11. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6 trial). New England Journal of Medicine. 2016.
12. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes (PIONEER 1 trial). JAMA. 2019.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.